Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2002-10-28
2010-02-23
Shiao, Rei-tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S322000, C514S397000, C514S403000, C548S362500, C548S311700, C544S116000, C546S199000
Reexamination Certificate
active
07666867
ABSTRACT:
One aspect of the invention is concerned with cannabimimetic heteroindane analogs having affinities and/or selectivities for a cannabinoid receptor. A further aspect of the invention is concerned with pharmaceutical preparations employing the inventive analogs and methods of administering therapeutically effective amounts of the inventive analogs to provide a physiological effect.
REFERENCES:
patent: 3041343 (1962-06-01), Jucker et al.
patent: 3465024 (1969-09-01), Brownstein et al.
patent: 3573327 (1971-03-01), Miyano
patent: 3577458 (1971-05-01), Brownstein et al.
patent: 3656906 (1972-04-01), Bullock
patent: 3838131 (1974-09-01), Gauthier
patent: 3886184 (1975-05-01), Matsumoto et al.
patent: 3897306 (1975-07-01), Vidic
patent: 3915996 (1975-10-01), Wright
patent: 3928598 (1975-12-01), Archer
patent: 3944673 (1976-03-01), Archer
patent: 3946029 (1976-03-01), Descamps et al.
patent: 3953603 (1976-04-01), Archer
patent: 4036857 (1977-07-01), Razdan et al.
patent: 4054582 (1977-10-01), Blanchard et al.
patent: 4087545 (1978-05-01), Archer et al.
patent: 4087546 (1978-05-01), Archer et al.
patent: 4087547 (1978-05-01), Archer et al.
patent: 4088777 (1978-05-01), Archer et al.
patent: 4102902 (1978-07-01), Archer et al.
patent: 4152450 (1979-05-01), Day et al.
patent: 4171315 (1979-10-01), Ryan
patent: 4176233 (1979-11-01), Archer et al.
patent: 4179517 (1979-12-01), Mechoulam
patent: 4188495 (1980-02-01), Althuis et al.
patent: 4208351 (1980-06-01), Archer et al.
patent: 4278603 (1981-07-01), Thakkar et al.
patent: 4282237 (1981-08-01), Silvestrini
patent: 4282248 (1981-08-01), Mechoulam et al.
patent: 4382943 (1983-05-01), Winter et al.
patent: 4395560 (1983-07-01), Ryan
patent: 4497827 (1985-02-01), Nelson
patent: 4550214 (1985-10-01), Mehta
patent: 4758597 (1988-07-01), Martin et al.
patent: 4812457 (1989-03-01), Narumiya
patent: 4876276 (1989-10-01), Mechoulam
patent: 4885295 (1989-12-01), Bell et al.
patent: 5017573 (1991-05-01), Kon et al.
patent: 5053548 (1991-10-01), Tanaka et al.
patent: 5068234 (1991-11-01), D'Ambra et al.
patent: 5147876 (1992-09-01), Mizuchi et al.
patent: 5223510 (1993-06-01), Gubin et al.
patent: 5272154 (1993-12-01), Dixon et al.
patent: 5278183 (1994-01-01), Silvestrini
patent: 5284867 (1994-02-01), Kloog
patent: 5324737 (1994-06-01), D'Ambra et al.
patent: 5434295 (1995-07-01), Mechoulam et al.
patent: 5440052 (1995-08-01), Makriyannis et al.
patent: 5462960 (1995-10-01), Barth et al.
patent: 5489580 (1996-02-01), Makriyannis et al.
patent: 5521215 (1996-05-01), Mechoulam
patent: 5532237 (1996-07-01), Gallant et al.
patent: 5538993 (1996-07-01), Mechoulam
patent: 5576436 (1996-11-01), McCabe et al.
patent: 5605906 (1997-02-01), Lau
patent: 5607933 (1997-03-01), D'Ambra et al.
patent: 5618955 (1997-04-01), Mechoulam et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5631297 (1997-05-01), Pate et al.
patent: 5635530 (1997-06-01), Mechoulam
patent: 5688825 (1997-11-01), Makriyannis et al.
patent: 5744459 (1998-04-01), Makriyannis et al.
patent: 5747524 (1998-05-01), Cullinan et al.
patent: 5760028 (1998-06-01), Jadhav et al.
patent: 5776932 (1998-07-01), Schindler et al.
patent: 5804601 (1998-09-01), Kato et al.
patent: 5817651 (1998-10-01), D'Ambra et al.
patent: 5872148 (1999-02-01), Makriyannis et al.
patent: 5874459 (1999-02-01), Makriyannis et al.
patent: 5925628 (1999-07-01), Lee et al.
patent: 5925768 (1999-07-01), Barth et al.
patent: 5932610 (1999-08-01), Shohami et al.
patent: 5939429 (1999-08-01), Kunos et al.
patent: 5948777 (1999-09-01), Bender et al.
patent: 6013648 (2000-01-01), Rinaldi et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6096740 (2000-08-01), Mechoulam
patent: 6127399 (2000-10-01), Yuan
patent: 6166066 (2000-12-01), Makriyannis et al.
patent: 6284788 (2001-09-01), Mittendorf et al.
patent: 6391909 (2002-05-01), Makriyannis et al.
patent: 6579900 (2003-06-01), Makriyannis et al.
patent: 6610737 (2003-08-01), Garzon et al.
patent: 6864291 (2005-03-01), Fride et al.
patent: 6897231 (2005-05-01), Bhagwat et al.
patent: 6903137 (2005-06-01), Fride et al.
patent: 2002/0119972 (2002-08-01), Leftheris et al.
patent: 2002/0173528 (2002-11-01), Fride et al.
patent: 2003/0120094 (2003-06-01), Makriyannis et al.
patent: 2003/0149082 (2003-08-01), Makriyannis et al.
patent: 2004/0077649 (2004-04-01), Makriyannis et al.
patent: 2004/0077851 (2004-04-01), Makriyannis et al.
patent: 2004/0087590 (2004-05-01), Makriyannis et al.
patent: 2004/0192667 (2004-09-01), Makriyannis et al.
patent: 2004/0236116 (2004-11-01), Makriyannis et al.
patent: 2160420 (1995-10-01), None
patent: 2222532 (1996-05-01), None
patent: 2304826 (1998-09-01), None
patent: 2 070 573 (2003-04-01), None
patent: 0276732 (1988-08-01), None
patent: 0444451 (1991-09-01), None
patent: 0471609 (1993-06-01), None
patent: 0576357 (1993-12-01), None
patent: 0737671 (1996-10-01), None
patent: 0860168 (2001-09-01), None
patent: 2240003 (1975-05-01), None
patent: 2735774 (2000-01-01), None
patent: 2027021 (1980-02-01), None
patent: 1995-113228 (1999-09-01), None
patent: 57098228 (1982-06-01), None
patent: 2304080 (1990-12-01), None
patent: WO 93/13099 (1993-07-01), None
patent: WO 94/12466 (1994-06-01), None
patent: WO 97/00860 (1997-01-01), None
patent: WO 97/21682 (1997-06-01), None
patent: WO 99/57106 (1999-11-01), None
patent: WO 99/57107 (1999-11-01), None
patent: WO 99/64389 (1999-12-01), None
patent: WO 00/32200 (2000-06-01), None
patent: WO 01/28329 (2001-04-01), None
patent: WO 01/28497 (2001-04-01), None
patent: WO 01/28498 (2001-04-01), None
patent: WO 01/28557 (2001-04-01), None
patent: WO 01/29007 (2001-04-01), None
patent: WO 01/32169 (2001-05-01), None
patent: WO 01/58869 (2001-08-01), None
patent: WO 02/058636 (2002-08-01), None
patent: WO 03/020217 (2003-03-01), None
patent: WO 03/063758 (2003-08-01), None
patent: WO 03/064359 (2003-08-01), None
Archer et al; “cannabinoids, synthesis approaches to 9-ketocannabinoids.”; J. Org. Chem.; vol. 42; No. 13; 2277-2284; (1977).
Mechoulam et al; “Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative”; Tetrahedron Asymmetry; 1:315-318; (1990) (abstract only).
European Search Report for Application No. EP 02 78 9293 dated Dec. 7, 2004.
Lan, R. et al; “Structure-Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists”; J. Med. Chem.; vol. 42(4); 769-776; (1999).
K. Kim et al.; “AM1241, a cannabinoid CB2receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis”; European Journal of Pharmacology 542 (2006) 100-105.
Bujalska, M. “Effect of Cannabinoid Receptor Agonists on Streptozotocin-Induced Hyperalgesia in Diabetic Neuropathy”.Pharmacology. 82, (3), 193-200, 2008.
Ibrahim, M. M., Deng, H., Zvonok, A., Cockayne, D. A., Kwan, J., Mata, H. P., Vanderah, T. W., Lai, J., Porreca, F., Makriyannis, A.; Malan, T. P., Jr. “Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS”.Proc. Natl. Acad. Sci. U. S. A.100, (18), 10529-10533, 2003.
Shoemaker, J. L., Seely, K. A., Reed, R. L., Crow, J. P.; Prather, P. L. “The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset”.J. Neurochem. 101, (1), 87-98, 2007.
Ashton, J. C.; Glass, M. “The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration”.Curr Neuropharmacol5, (2), 73-80, 2007.
Benito, C., Tolon, R. M., Pazos, M. R., Nunez, E., Castillo, A. I.; Romero, J. “Cannabinoid CB2 receptors in human brain inflammation”.Br J Pharmacol153, (2), 277-85, 2008.
Fernandez-Ruiz, J., Pazos, M. R., Garcia-Arencibia, M., Sagredo, O.; Ramos, J. A. “Role of CB2 receptors in neuroprotective effects of cannabinoids”.Mol Cell Endocrinol286, (1-2 Suppl 1), S91-6, 2008.
Marchalant, Y., Rosi, S.; Wenk, G. L. “Anti-inflamma
Liu Qian
Makriyannis Alexandros
Zvonok Alexander M
Alix Yale & Ristas, LLP
Shiao Rei-tsang
University of Connecticut
LandOfFree
Heteroindanes: a new class of potent cannabimimetic ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroindanes: a new class of potent cannabimimetic ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroindanes: a new class of potent cannabimimetic ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4195662